Press

Media Relations

If you are a journalist with a question about Lundbeck or would like to request an interview, please contact Media Relations – and we will get back to you. Please note this service is for journalists and other media professionals only. Please kindly note all other requests to this e-mail will not receive a response.

For general press enquiries, call us at +45 3643 4000

Contact Medial Relation

Thomas Mikkel Mortensen

media relations lead

About Lundbeck

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

 

Millions of people worldwide live with brain diseases, and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement, and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases.

 

Our approximately 5,400 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs, and our products are available in more than 100 countries. We have research centers in Denmark and the US, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 18.2 billion in 2022 (EUR 2.4 billion; USD 2.6 billion)

 

For additional information, we encourage you to connect with us on Twitter at @Lundbeck and via LinkedIn.

Media Library

Pictures of our Executive Management, videos, and other assets for download and distribution.

Communication policy

We engage in an open, constructive and continuous dialogue with our stakeholders based on equality and mutual respect.

FACTS ABOUT LUNDBECK

70 years

In front of neuroscience research

100

Countries of operation around the world

5,400

Employees worldwide

18.2 b DKK

Of revenue generated in 2022